Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) Equity Ratio (2022 - 2025)

Historic Equity Ratio for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to 0.77.

  • Zentalis Pharmaceuticals' Equity Ratio fell 172.0% to 0.77 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.77, marking a year-over-year decrease of 172.0%. This contributed to the annual value of 0.78 for FY2024, which is 117.1% down from last year.
  • Zentalis Pharmaceuticals' Equity Ratio amounted to 0.77 in Q3 2025, which was down 172.0% from 0.78 recorded in Q2 2025.
  • In the past 5 years, Zentalis Pharmaceuticals' Equity Ratio ranged from a high of 0.84 in Q2 2023 and a low of 0.77 during Q1 2025
  • Over the past 4 years, Zentalis Pharmaceuticals' median Equity Ratio value was 0.79 (recorded in 2023), while the average stood at 0.8.
  • Data for Zentalis Pharmaceuticals' Equity Ratio shows a peak YoY increase of 441.66% (in 2024) and a maximum YoY decrease of 759.25% (in 2024) over the last 5 years.
  • Zentalis Pharmaceuticals' Equity Ratio (Quarter) stood at 0.8 in 2022, then dropped by 1.49% to 0.79 in 2023, then dropped by 1.17% to 0.78 in 2024, then decreased by 1.38% to 0.77 in 2025.
  • Its last three reported values are 0.77 in Q3 2025, 0.78 for Q2 2025, and 0.77 during Q1 2025.